Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Multicenter, Randomized, Open-label Phase III Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT06834672
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:26:37.209586+00:00
Published At
2025-04-13T00:00:00+00:00
Record Updated At
2025-04-13
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Ovarian", "Primary Peritoneal", "Fallopian Tube Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-04-13"
protocolSection.identificationModule.nctId
"NCT06834672"
protocolSection.identificationModule.officialTitle
"A Multicenter, Randomized, Open-label Phase III Study of IBI354 Versus Investigator\u0027s Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Ovarian (protocolSection.conditionsModule.conditions)
  • Primary Peritoneal (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Cancer (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.